Related Experiment Video
Updated: Jul 9, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
The Relevance of Cancer-Type-Specific Scenarios in Predicting Primary Radiotherapy Use in Nonmetastatic Cancer
H Struikmans1, J Evers2, J W Bauhuis2
1Department of Radiation Oncology, Leiden University Medical Centre, Leiden, The Netherlands.
Aims:
The aim of this study was to predict primary radiotherapy (RT) use in the Netherlands for patients with nonmetastatic cancer. Additionally, we explore its associations with predefined scenarios for five types of cancers.
Materials And Methods:
Cancer incidences in 2032 were predicted based on data from Netherlands Cancer Registry and Statistics Netherlands according to an age-period-cohort model. In the prediction of the number of patients to receive primary RT, a random forest model was used. First, primary RT use towards 2032 was predicted for all nonmetastatic cancers assuming historical trends to be representative for the future (the base prediction). Next, primary RT use was predicted for five types of cancer by applying predefined scenarios.
Results:
According to the base prediction, overall primary RT use in nonmetastatic cancers increased by 23% in 2032. Increased RT use was predicted in non-small cell lung cancer (NSCLC) stages I (+55%) and II (+230%), ductal carcinoma in situ (DCIS) grade I-II (+64%) and grade III (+22%), breast cancer stage I-III (+10%), localised intermediate-risk prostate cancer (external beam radiotherapy [EBRT] use +22%), brachytherapy (BT) use (+10%), locally advanced prostate cancer (EBRT use +29%), and BT use (+15%). Decreased RT use was predicted in NSCLC stage III (-13%) as well as in localised high-risk prostate cancer (-19%) and remained unaltered in localised low-risk prostate cancer. Compared to the base prediction, predefined cancer-type-specific scenarios showed RT use in NSCLC stages I and III to increase further (+18%) and to decrease further (-7%), respectively; a decreased RT use in low-risk DCIS (-61%) and in low-risk breast cancer (-15%); and a decreased as well as an increased RT use in prostate cancer. For rectal cancer a decreased RT-use is foreseen.
Conclusion:
The magnitude of the predicted use of primary RT towards 2032 varies substantially by cancer type and depends strongly on cancertype-specific scenarios. This underscores the importance of incorporating such scenarios to generate more accurate estimates of future workload for RT departments.
Related Concept Videos
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
